The pneumococcal infection market is on the rise due to high disease burden, antimicrobial resistance, and vaccination campaigns. Key players like Gangagen, CanSino Biologics, and GlaxoSmithKline are developing promising therapies like klebicins and PBPV. Companies like SK bioscience and Vaxcyte are advancing clinical trials for new vaccines, targeting both pediatric and adult populations. DelveInsight’s report provides comprehensive insights into the pneumococcal infections pipeline, offering valuable information on emerging treatments and market trends.

Read more at GlobeNewswire: Pneumococcal Infections Clinical Trial Analysis: Key